Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group

G. Bisogno, V. Minard-Colin, MB. Arush, J. Daragjati, B. Coppadoro, S. Gallego, R. Alaggio, N. Smeulders, P. Mudry, A. Zin, JHM. Merks, O. Slater

. 2022 ; 69 (2) : e29376. [pub] 20210928

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019450

PROCEDURE: Congenital rhabdomyosarcoma (RMS) represents a challenging disease due to its characteristics and the difficulties in delivering treatment in this immature population. METHODS: We analyzed treatment and outcome of patients with congenital RMS, defined as tumor diagnosed in the first 2 months of life, enrolled in the European paediatric Soft tissue sarcoma Study Group protocols. RESULTS: Twenty-four patients with congenital RMS were registered. All, except one patient (PAX3-FOXO1-positive metastatic RMS), had favorable histology and localized disease. Three patients had VGLL2-CITED2/NCOA2 fusion. Complete tumor resection was achieved in 10 patients. No radiotherapy was given. Chemotherapy doses were adjusted to age and weight. Only two patients required further dose reduction for toxicity. The 5-year event-free survival (EFS) and overall survival (OS) were 75.0% (95% confidence interval [CI] 52.6-87.9) and 87.3% (95% CI 65.6-95.7), respectively. Progressive disease was the main cause of treatment failure. CONCLUSION: Patients with congenital RMS presented with a favorable disease, allowing weight- and age-adjusted doses of chemotherapy and avoidance of irradiation, without compromising the outcome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019450
003      
CZ-PrNML
005      
20220804135654.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.29376 $2 doi
035    __
$a (PubMed)34582098
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bisogno, Gianni $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padua, Italy $1 https://orcid.org/0000000344625523
245    10
$a Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group / $c G. Bisogno, V. Minard-Colin, MB. Arush, J. Daragjati, B. Coppadoro, S. Gallego, R. Alaggio, N. Smeulders, P. Mudry, A. Zin, JHM. Merks, O. Slater
520    9_
$a PROCEDURE: Congenital rhabdomyosarcoma (RMS) represents a challenging disease due to its characteristics and the difficulties in delivering treatment in this immature population. METHODS: We analyzed treatment and outcome of patients with congenital RMS, defined as tumor diagnosed in the first 2 months of life, enrolled in the European paediatric Soft tissue sarcoma Study Group protocols. RESULTS: Twenty-four patients with congenital RMS were registered. All, except one patient (PAX3-FOXO1-positive metastatic RMS), had favorable histology and localized disease. Three patients had VGLL2-CITED2/NCOA2 fusion. Complete tumor resection was achieved in 10 patients. No radiotherapy was given. Chemotherapy doses were adjusted to age and weight. Only two patients required further dose reduction for toxicity. The 5-year event-free survival (EFS) and overall survival (OS) were 75.0% (95% confidence interval [CI] 52.6-87.9) and 87.3% (95% CI 65.6-95.7), respectively. Progressive disease was the main cause of treatment failure. CONCLUSION: Patients with congenital RMS presented with a favorable disease, allowing weight- and age-adjusted doses of chemotherapy and avoidance of irradiation, without compromising the outcome.
650    _2
$a dítě $7 D002648
650    _2
$a fúze genů $7 D050939
650    _2
$a lidé $7 D006801
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a represorové proteiny $7 D012097
650    12
$a rhabdomyosarkom $x patologie $7 D012208
650    12
$a embryonální rhabdomyosarkom $7 D018233
650    _2
$a trans-aktivátory $7 D015534
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Minard-Colin, Veronique $u Department of Paediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France $1 https://orcid.org/0000000202965207
700    1_
$a Arush, Myriam Ben $u Joan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel $1 https://orcid.org/0000000280444167
700    1_
$a Daragjati, Julia $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padua, Italy
700    1_
$a Coppadoro, Beatrice $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padua, Italy
700    1_
$a Gallego, Soledad $u Servicio de Oncología y Hematología Pediatrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain $1 https://orcid.org/0000000247129624
700    1_
$a Alaggio, Rita $u Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy $1 https://orcid.org/0000000339153816
700    1_
$a Smeulders, Naima $u Departments of Paediatric Oncology and Paediatric Urology, Great Ormond Street Hospital for Children, London, UK
700    1_
$a Mudry, Peter $u Pediatric Oncology Department, Children's Hospital Brno, Brno, Czech Republic
700    1_
$a Zin, Angelica $u Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padua, Italy
700    1_
$a Merks, Johannes H M $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
700    1_
$a Slater, Olga $u Departments of Paediatric Oncology and Paediatric Urology, Great Ormond Street Hospital for Children, London, UK
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 69, č. 2 (2022), s. e29376
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34582098 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135648 $b ABA008
999    __
$a ok $b bmc $g 1822873 $s 1170693
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 69 $c 2 $d e29376 $e 20210928 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace